Cited by 189Barrier Structure and Function StudiesParkinson's Disease Mechanisms and TreatmentsNuclear Receptors and Signaling

The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.

Caffeine protects against MPTP‐induced blood‐brain barrier dysfunction in mouse striatum

Open access

Chen, Xuesong, Lan, Xun, Roche, Ian, Liu, Rugao, Geiger, Jonathan D.·2008·Journal of Neurochemistry

DOI 10.1111/j.1471-4159.2008.05697.xPMC PMC3692355

Open this paper in CoChat — free account

Abstract

The blood‐brain barrier (BBB) is important physiologically. Pathologically, BBB disruption has been implicated in a wide spectrum of neurological disorders including Parkinson’s disease (PD). Recent studies indicate that caffeine is protective against PD, but by poorly understood mechanisms. Using a MPTP neurotoxin model of PD we tested the hypothesis that the protective actions of caffeine were because of, at least in part, preventing MPTP‐induced BBB dysfunction. FVB mice were pre‐treated with caffeine (10 mg/kg, i.p.) or saline for 7 days prior to initiation of neurotoxin treatments; during the 7 days of neurotoxin treatment, caffeine or saline continued to be administered 10 min before each dose of MPTP (20 mg/kg, i.p.). Striatum (and for some studies hippocampus and cerebral cortex as well) were evaluated for BBB leakage, tight junction protein expression levels, integrity of dopaminergic neurons, and activation of astrocytes and microglia using immunostaining, immunoblotting and real‐time PCR techniques. We found that caffeine blocked MPTP‐induced decreases in numbers of tyrosine hydroxylase‐positive dopaminergic neurons, increases in leakage of Evan’s blue dye and FITC‐albumin in striatum but not in cerebral cortex or hippocampus, decreases in levels of the tight junction proteins occludin and ZO‐1, and increases in reactive gliosis. Our results suggest that caffeine might protect against PD and PD‐like features in animal models, in part, by stabilizing the BBB.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1111/j.1471-4159.2008.05697.x

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Astrocyte-endothelial interactions at the blood-brain barrier
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1824 · Cited by 5,595
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280
Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
The blood-brain barrier/neurovascular unit in health and disease
Hawkins, B. T., & Davis, T. P. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.4 · Cited by 2,661
Actions of caffeine in the brain with special reference to factors that contribute to its widespread use
Fredholm, B. B., Bättig, K., Holmén, J., Nehlig, A., & Zvartau, E. E. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01396-6 · Cited by 2,624
Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects
Nehlig, A., Daval, J., & Debry, G. (1992) · Brain Research Reviews · doi:10.1016/0165-0173(92)90012-b · Cited by 1,463
Risk Factors for Alzheimer's Disease: A Prospective Analysis from the Canadian Study of Health and Aging
Lindsay, J. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf074 · Cited by 1,261
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200
Coffee and Health: A Review of Recent Human Research
Higdon, J. V., & Frei, B. (2006) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408390500400009 · Cited by 1,090
Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease
Liberatore, G. T., Jackson-Lewis, V., Vukosavic, S., Mandir, A. S., Vila, M., McAuliffe, W. G., Dawson, V. L., Dawson, T. M., & Przedborski, S. (1999) · Nature Medicine · doi:10.1038/70978 · Cited by 1,046

Show all 71 references

Sorted by citations

Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Blood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,312
Adenosine receptors as drug targets — what are the challenges?
Chen, J., Eltzschig, H. K., & Fredholm, B. B. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3955 · Cited by 923
Caffeine: Cognitive and Physical Performance Enhancer or Psychoactive Drug?
Cappelletti, S., Daria, P., Sani, G., & Aromatario, M. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666141210215655 · Cited by 631
“In epidemiological reports, caffeine consumption was associated with a significantly lower risk of developing them [4, 11, 12, 120-122, 124].”
Background
Astrocytic modulation of blood brain barrier: perspectives on Parkinson’s disease
Cabezas, R., Ávila, M. F., González, J., El-Bachá, R. D. S., Báez-Jurado, E., García‐Segura, L. M., Jurado-Coronel, J. C., Capani, F., Cardona‐Gómez, G. P., & Barreto, G. E. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00211 · Cited by 481
Structure, Function, and Regulation of the Blood-Brain Barrier Tight Junction in Central Nervous System Disorders
Lochhead, J. J., Yang, J., Ronaldson, P. T., & Davis, T. P. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00914 · Cited by 445
Adenosine receptors and brain diseases: neuroprotection and neurodegeneration
Gomes, C. V., Kaster, M. P., Tomé, A. R., Agostinho, P. M., & Cunha, R. A. (2011) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2010.12.001 · Cited by 419
Evolution of blood–brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies
Han, L., & Jiang, C. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.11.023 · Cited by 358
The effects of a high-energy diet on hippocampal function and blood-brain barrier integrity in the rat
Kanoski, S. E., Zhang, Y., Zheng, W., & Davidson, T. L. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091414 · Cited by 324
The blood–brain barrier in neurodegenerative disease: a rhetorical perspective
Carvey, P. M., Hendey, B., & Monahan, A. J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06319.x · Cited by 260
Neuroprotective Effects of Coffee Bioactive Compounds: A Review
Socała, K., Szopa, A., Serefko, A., Poleszak, E., & Właź, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010107 · Cited by 271
Losing your nerves? Maybe it's the antibodies
Diamond, B., Huerta, P. T., Mina-Osorio, P., Kowal, C., & Volpe, B. T. (2009) · Nature Reviews Immunology · doi:10.1038/nri2529 · Cited by 247
Neurovascular Unit Dysfunction and Neurodegenerative Disorders
Yu, X., Ji, C., & Shao, A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00334 · Cited by 244
Caffeine effects on systemic metabolism, oxidative-inflammatory pathways, and exercise performance
Barcelos, R. P., Lima, F. D., de Carvalho, N. R., Bresciani, G., & Royes, L. F. F. (2020) · Nutrition Research · doi:10.1016/j.nutres.2020.05.005 · Cited by 248
Sodium butyrate exerts protective effect against Parkinson's disease in mice via stimulation of glucagon like peptide-1
Liu, J., Wang, F., Liu, S., Du, J., Hu, X., Xiong, J., Fang, R., Chen, W., & Sun, J. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.08.3235 · Cited by 218
Cellular and molecular mechanisms of the blood–brain barrier dysfunction in neurodegenerative diseases
Chen, T., Dai, Y., Hu, C., Lin, Z., Wang, S., Yang, J., Zeng, L., Li, S., & Li, W. (2024) · Fluids and Barriers of the CNS · doi:10.1186/s12987-024-00557-1 · Cited by 205
Neuroinflammation and Parkinson’s Disease—From Neurodegeneration to Therapeutic Opportunities
Araújo, B., Caridade-Silva, R., Soares-Guedes, C., Martins‐Macedo, J., Gomes, E. D., Monteiro, S., & Teixeira, F. G. (2022) · Cells · doi:10.3390/cells11182908 · Cited by 209
Antidepressant-like effects of sodium butyrate and its possible mechanisms of action in mice exposed to chronic unpredictable mild stress
Sun, J., Wang, F., Hong, G., Pang, M., Xu, H., Li, H., Tian, F., Fang, R., Yao, Y., & Liu, J. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.03.003 · Cited by 184
Structure-Bioactivity Relationships of Methylxanthines: Trying to Make Sense of All the Promises and the Drawbacks
Monteiro, J., Alves, M. G., Oliveira, P. F., & Silva, B. M. (2016) · Molecules · doi:10.3390/molecules21080974 · Cited by 195
Fluoxetine inhibits matrix metalloprotease activation and prevents disruption of blood–spinal cord barrier after spinal cord injury
Lee, J. Y., Kim, H. S., Choi, H. Y., Oh, T. H., & Yune, T. Y. (2012) · Brain · doi:10.1093/brain/aws171 · Cited by 164
Caffeine protects against oxidative stress and Alzheimer's disease-like pathology in rabbit hippocampus induced by cholesterol-enriched diet
Prasanthi, J. R. P., Dasari, B., Marwarha, G., Larson, T., Chen, X., Geiger, J. D., & Ghribi, O. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.07.007 · Cited by 164
Self-citation
Astrocyte alterations in neurodegenerative pathologies and their modeling in human induced pluripotent stem cell platforms
Oksanen, M., Lehtonen, Š., Jaronen, M., Goldsteins, G., Hämäläinen, R. H., & Koıstınaho, J. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03111-7 · Cited by 166
Blood–brain barrier alterations and their impact on Parkinson’s disease pathogenesis and therapy
Lau, K., Kotzur, R., & Richter, F. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00430-z · Cited by 174
Caffeine and Parkinson’s Disease: Multiple Benefits and Emerging Mechanisms
Ren, X., & Chen, J. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.602697 · Cited by 167
The role of neuroinflammation on the pathogenesis of Parkinson's disease
Chung, Y. C., Ko, H. W., Bok, E., Park, E. S., Huh, S. H., Nam, J. H., & Jin, B. K. (2010) · BMB Reports · doi:10.5483/bmbrep.2010.43.4.225 · Cited by 149
Adenosine receptor signaling: a key to opening the blood–brain door
Bynoe, M. S., Viret, C., Yan, A., & Kim, D.-G. (2015) · Fluids and Barriers of the CNS · doi:10.1186/s12987-015-0017-7 · Cited by 143
Evidence for angiogenesis in Parkinson’s disease, incidental Lewy body disease, and progressive supranuclear palsy
Desai Bradaric, B., Patel, A., Schneider, J. A., Carvey, P. M., & Hendey, B. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-011-0684-8 · Cited by 139
Impact of aging, Alzheimer's disease and Parkinson's disease on the blood-brain barrier transport of therapeutics
Pan, Y., & Nicolazzo, J. A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.04.009 · Cited by 131
Caffeine as symptomatic treatment for Parkinson disease (Café-PD): A randomized trial
Postuma, R. B., Anang, J., Pelletier, A., Joseph, L., Moscovich, M., Grimes, D., Furtado, S., Munhoz, R. P., Appel-Cresswell, S., Moro, A., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004568 · Cited by 135
Caffeine Protects Against Disruptions of the Blood-Brain Barrier in Animal Models of Alzheimer's and Parkinson's Diseases
Chen, X., Ghribi, O., & Geiger, J. D. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1376 · Cited by 137
Self-citation
Relationship between the Chemical Composition and the Biological Functions of Coffee
Saud, S., & Salamatullah, A. M. (2021) · Molecules · doi:10.3390/molecules26247634 · Cited by 133
Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease
Xu, K., Xu, Y.-H., Chen, J., & Schwarzschild, M. A. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.02.020 · Cited by 140
Matrix metalloproteinase-9 inhibition prevents aquaporin-4 depolarization-mediated glymphatic dysfunction in Parkinson’s disease
Si, X., Dai, S., Fang, Y., Tang, J., Wang, Z., Li, Y., Song, Z., Chen, Y., Liu, Y., Zhao, G., et al. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.03.004 · Cited by 138
Valproic acid attenuates blood–spinal cord barrier disruption by inhibiting matrix metalloprotease‐9 activity and improves functional recovery after spinal cord injury
Lee, J. Y., Kim, H. S., Choi, H. Y., Oh, T. H., Ju, B. G., & Yune, T. Y. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07731.x · Cited by 131
Human α-synuclein overexpression in a mouse model of Parkinson’s disease leads to vascular pathology, blood brain barrier leakage and pericyte activation
Elabi, O. F., Gaceb, A., Carlsson, R., Padel, T., Soylu-Kucharz, R., Cortijo, I., Li, W., Li, J., & Paul, G. (2021) · Scientific Reports · doi:10.1038/s41598-020-80889-8 · Cited by 131
Astrocytic VEGFA : An essential mediator in blood–brain‐barrier disruption in Parkinson's disease
Lan, G., Wang, P., Chan, R. B., Liu, Z., Yu, Z., Liu, X., Yang, Y., & Zhang, J. (2022) · Glia · doi:10.1002/glia.24109 · Cited by 122
CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson’s disease
Chung, Y. C., Shin, W.-H., Baek, J. Y., Cho, E. J., Baik, H. H., Kim, S. R., Won, S.-Y., & Jin, B. K. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2015.100 · Cited by 126
Blood-brain barrier receptors and transporters: an insight on their function and how to exploit them through nanotechnology
Moura, R. P., Martins, C., Pinto, S. F. T., Sousa, F., & Sarmento, B. F. C. C. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1583205 · Cited by 127
Deep-brain stimulation associates with improved microvascular integrity in the subthalamic nucleus in Parkinson's disease
Pienaar, I. S., Lee, C. H., Elson, J. L., McGuinness, L., Gentleman, S. M., Kalaria, R. N., & Dexter, D. T. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.12.006 · Cited by 125
Adenosine receptor neurobiology: overview
Chen, J.-F., Lee, C.-F., & Chern, Y. (2014) · International review of neurobiology · doi:10.1016/b978-0-12-801022-8.00001-5 · Cited by 119
Dendritic Degeneration, Neurovascular Defects, and Inflammation Precede Neuronal Loss in a Mouse Model for Tau-Mediated Neurodegeneration
Jaworski, T., Lechat, B., Demedts, D., Gielis, L., Devijver, H., Borghgraef, P., Duimel, H., Verheyen, F., Kügler, S., & LEUVEN, F. V. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.06.025 · Cited by 121
Pathological overproduction: the bad side of adenosine
Borea, P. A., Gessi, S., Merighi, S., Vincenzi, F., & Varani, K. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13763 · Cited by 118
Caffeine Induces Neurobehavioral Effects through Modulating Neurotransmitters
Alasmari, F. (2020) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2020.02.005 · Cited by 113
“For example, it has been found that there are marked improvements in behavioral responses in a rat model of ADHD following exposure to caffeine (Pandolfo et al., 2013).”
Influential
Pharmacological potential of methylxanthines: Retrospective analysis and future expectations
Monteiro, J., Alves, M. G., Oliveira, P. F., & Silva, B. M. (2018) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2018.1461607 · Cited by 104
The Blood–Brain Barrier and Its Intercellular Junctions in Age-Related Brain Disorders
Costea, L., Mészáros, Á., Bauer, H., Bauer, H., Traweger, A., Wilhelm, I., Farkas, A. E., & Krizbai, I. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215472 · Cited by 102
Disruption of the blood-brain barrier in parkinson's disease: curse or route to a cure?
Lee, H. (2014) · Frontiers in bioscience · doi:10.2741/4206 · Cited by 96
Microvascular Changes in Parkinson’s Disease- Focus on the Neurovascular Unit
Paul, G., & Elabi, O. F. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.853372 · Cited by 98
MMP-3 Contributes to Nigrostriatal Dopaminergic Neuronal Loss, BBB Damage, and Neuroinflammation in an MPTP Mouse Model of Parkinson’s Disease
Chung, Y. C., Kim, Y.-S., Bok, E., Yune, T. Y., Maeng, S., & Jin, B. K. (2013) · Mediators of Inflammation · doi:10.1155/2013/370526 · Cited by 94
Potential role of gut microbiota and tissue barriers in Parkinson's disease and amyotrophic lateral sclerosis
Fang, X. (2015) · International Journal of Neuroscience · doi:10.3109/00207454.2015.1096271 · Cited by 84
Parkinson's Disease Phenotypes in Patient Neuronal Cultures and Brain Organoids Improved by 2‐Hydroxypropyl‐β‐Cyclodextrin Treatment
Jarazo, J., Barmpa, K., Modamio, J., Saraiva, C., Sabaté‐Soler, S., Rosety, I., Griesbeck, A., Skwirblies, F., Zaffaroni, G., Smits, L. M., et al. (2021) · Movement Disorders · doi:10.1002/mds.28810 · Cited by 98
Impacts of Methylxanthines and Adenosine Receptors on Neurodegeneration: Human and Experimental Studies
Chen, J., & Chern, Y. (2010) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-13443-2_10 · Cited by 85
Healthy Human Fecal Microbiota Transplantation into Mice Attenuates MPTP-Induced Neurotoxicity via AMPK/SOD2 Pathway
Xie, Z., Zhang, M., Luo, Y., Jin, D., Guo, X., Yang, W., Zheng, J., Zhang, H., Zhang, L., Deng, C., et al. (2023) · Aging and disease · doi:10.14336/ad.2023.0309 · Cited by 80
Having a Coffee Break: The Impact of Caffeine Consumption on Microglia-Mediated Inflammation in Neurodegenerative Diseases
Madeira, M. H., Boia, R., Ambrósio, A. F., & Santiago, A. R. (2017) · Mediators of Inflammation · doi:10.1155/2017/4761081 · Cited by 87
Fluoxetine inhibits transient global ischemia-induced hippocampal neuronal death and memory impairment by preventing blood–brain barrier disruption
Lee, J. Y., Lee, H. E., Kang, S. R., Choi, H. Y., Ryu, J. H., & Yune, T. Y. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.11.011 · Cited by 78
In vitro models and systems for evaluating the dynamics of drug delivery to the healthy and diseased brain
Modarres, H. P., Janmaleki, M., Novin, M., Saliba, J., Moussa, F. E. H., Charan, M. R., Seyfoori, A., SadAbadi, H., Vandal, M., Nguyen, M. D., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.01.024 · Cited by 77
Genetic inactivation of the adenosine A2A receptor exacerbates brain damage in mice with experimental autoimmune encephalomyelitis
Yao, S., Li, Z.-Z., Huang, Q., Li, F., Wang, Z., Augusto, E., He, J., Wang, X., Chen, J., & Zheng, R. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07807.x · Cited by 75
Platelet-derived growth factor-BB has neurorestorative effects and modulates the pericyte response in a partial 6-hydroxydopamine lesion mouse model of Parkinson's disease
Padel, T., Özen, I., Boix, J., Barbariga, M., Gaceb, A., Roth, M., & Paul, G. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.06.002 · Cited by 70
Human Bone Marrow Mesenchymal Stem Cell–Derived Exosomes Attenuate Blood–Spinal Cord Barrier Disruption via the TIMP2/MMP Pathway After Acute Spinal Cord Injury
Wang, X., Qiang, S., Jianing, D., Jiaming, L., Lin, F., Cai, B., Yuanyuan, C., Guowang, Z., Xu, J., & Xiaofeng, L. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02565-w · Cited by 67
Pre-conditioning with Remote Photobiomodulation Modulates the Brain Transcriptome and Protects Against MPTP Insult in Mice
Ganeshan, V., Skladnev, N. V., Kim, J. Y., Mitrofanis, J., Stone, J., & Johnstone, D. M. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2018.12.050 · Cited by 67
Role of Secondary Mediators in Caffeine-Mediated Neuroprotection in Maneb- and Paraquat-Induced Parkinson’s Disease Phenotype in the Mouse
Yadav, S., Gupta, S. P., Srivastava, G., Srivastava, P. K., & Singh, M. P. (2011) · Neurochemical Research · doi:10.1007/s11064-011-0682-0 · Cited by 69
Current Status and Challenges Associated with CNS-Targeted Gene Delivery across the BBB
Kimura, S., & Harashima, H. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121216 · Cited by 65
Endolysosome involvement in LDL cholesterol-induced Alzheimer's disease-like pathology in primary cultured neurons
Hui, L., Chen, X., & Geiger, J. D. (2012) · Life Sciences · doi:10.1016/j.lfs.2012.04.039 · Cited by 58
Self-citation
Animal Models of Metabolic Disorders in the Study of Neurodegenerative Diseases: An Overview
Bem, A. F. D., Krolow, R., Farias, H. R., de Rezende, V. L., Gelain, D. P., Moreira, J. C. F., Duarte, J. M. N., & de Oliveira, J. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.604150 · Cited by 69
High glucose, glucose fluctuation and carbonyl stress enhance brain microvascular endothelial barrier dysfunction: Implications for diabetic cerebral microvasculature
Li, W., Maloney, R. E., & Aw, T. Y. (2015) · Redox Biology · doi:10.1016/j.redox.2015.03.005 · Cited by 63
Can coffee consumption lower the risk of Alzheimer’s disease and Parkinson’s disease? A literature review
Wierzejska, R. E. (2017) · Archives of Medical Science · doi:10.5114/aoms.2016.63599 · Cited by 63
Opioid system influences gut-brain axis: Dysbiosis and related alterations
Rueda‐Ruzafa, L., Cruz, F., Cardona, D., Hone, A. J., Molina‐Torres, G., Sánchez‐Labraca, N., & Román, P. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104928 · Cited by 65
Catalpol Exerts a Neuroprotective Effect in the MPTP Mouse Model of Parkinson’s Disease
Wang, L., Yu, X., Li, X., Zhao, Y., Wang, C., Wang, Z., & He, Z. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00316 · Cited by 61
Tight junctions in neurological diseases
Bednarczyk, J., & Łukasiuk, K. (2011) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2011-1861 · Cited by 64
Very High Resolution Ultrasound Imaging for Real-Time Quantitative Visualization of Vascular Disruption after Spinal Cord Injury
Soubeyrand, M., Badner, A., Vawda, R., Chung, Y. S., & Fehlings, M. G. (2014) · Journal of Neurotrauma · doi:10.1089/neu.2013.3319 · Cited by 56
High-fat diet-induced diabetes leads to vascular alterations, pericyte reduction, and perivascular depletion of microglia in a 6-OHDA toxin model of Parkinson disease
Elabi, O. F., da Cunha, J. P. M. C. M., Gaceb, A., Fex, M., & Paul, G. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02218-8 · Cited by 58
Blood–brain barrier opening with focused ultrasound in experimental models of Parkinson's disease
Karakatsani, M. E., Blesa, J., & Konofagou, E. E. (2019) · Movement Disorders · doi:10.1002/mds.27804 · Cited by 58
Peripheral Inflammation Increases the Damage in Animal Models of Nigrostriatal Dopaminergic Neurodegeneration: Possible Implication in Parkinson's Disease Incidence
Machado, A., Herrera, A. J., Venero, J. L., Santiago, M., de Pablos, R. M., Villarán, R. F., Espinosa‐Oliva, A. M., Argüelles, S., Sarmiento, M., Delgado‐Cortés, M. J., et al. (2011) · Parkinson s Disease · doi:10.4061/2011/393769 · Cited by 54
Neuroprotective effects of caffeine in MPTP model of Parkinson's disease: A 13 C NMR study
Bagga, P., Chugani, A. N., & Patel, A. B. (2015) · Neurochemistry International · doi:10.1016/j.neuint.2015.11.006 · Cited by 50
Epidermal growth factor attenuates blood‐spinal cord barrier disruption via PI 3K/Akt/Rac1 pathway after acute spinal cord injury
Zheng, B., Ye, L., Zhou, Y., Zhu, S., Wang, Q., Shi, H., Chen, D., Wei, X., Wang, Z., Li, X., et al. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12761 · Cited by 52
Caffeine and a selective adenosine A2A receptor antagonist induce sensitization and cross-sensitization behavior associated with increased striatal dopamine in mice
Hsu, C. W., Wang, C. S., & Chiu, T. H. (2010) · Journal of Biomedical Science · doi:10.1186/1423-0127-17-4 · Cited by 49
Neurodegenerative Diseases: Can Caffeine Be a Powerful Ally to Weaken Neuroinflammation?
Ruggiero, M., Calvello, R., Porro, C., Messina, G., Cianciulli, A., & Panaro, M. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112958 · Cited by 59
Purinergic signaling: A gatekeeper of blood-brain barrier permeation
Wang, Y., Zhu, Y., Wang, J., Dong, L., Liu, S., Li, S., & Wu, Q. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1112758 · Cited by 47
Caffeine: An Overview of Its Beneficial Effects in Experimental Models and Clinical Trials of Parkinson’s Disease
Schepici, G., Silvestro, S., Bramanti, P., & Mazzon, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134766 · Cited by 48
Epidemiologie und Ursachen der Parkinson-Erkrankung
Lill, C. M., & Klein, C. (2017) · Der Nervenarzt · doi:10.1007/s00115-017-0288-0 · Cited by 47
Effects of Poly (ADP-ribose) Polymerase Inhibitor 3-Aminobenzamide on Blood–Brain Barrier and Dopaminergic Neurons of Rats with Lipopolysaccharide-Induced Parkinson’s Disease
Wu, X., Wang, P., Liu, Y., & Xue, Y. (2013) · Journal of Molecular Neuroscience · doi:10.1007/s12031-013-0175-5 · Cited by 44
The Janus face of caffeine
Porciúncula, L. O., Sallaberry, C., Mioranzza, S., Botton, P. H. S., & Rosemberg, D. B. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.09.009 · Cited by 45
Human brain endothelial cells are responsive to adenosine receptor activation
Mills, J. H., Alabanza, L. M., Weksler, B. B., Couraud, P., Romero, I. A., & Bynoe, M. S. (2011) · Purinergic Signalling · doi:10.1007/s11302-011-9222-2 · Cited by 43
Korean red ginseng suppresses 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced inflammation in the substantia nigra and colon
Jeon, H., Bae, C., Lee, Y., Kim, H.-Y., & Kim, S. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.02.028 · Cited by 45
Unveiling the impact of aging on BBB and Alzheimer's disease: Factors and therapeutic implications
Jha, N. K., Jha, N. K., Nuli, M. V., Gupta, S. K., Kanna, S., Gahtani, R. M., Hani, U., Singh, A. K., Abomughaid, M. M., Abomughayedh, A. M., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102224 · Cited by 43
Homeostatic bioenergetic network regulation: a novel concept to avoid pharmacoresistance in epilepsy
Boison, D., Masino, S. A., & Geiger, J. D. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.575777 · Cited by 38
Self-citation
Plant-Derived Natural Products for Parkinson’s Disease Therapy
Sengupta, T. K., Vinayagam, J., Singh, R. P., Jaisankar, P., & Mohanakumar, K. P. (2016) · Advances in neurobiology · doi:10.1007/978-3-319-28383-8_23 · Cited by 39
Interleukin-4 Contributes to Degeneration of Dopamine Neurons in the Lipopolysaccharide-treated Substantia Nigrain vivo
Bok, E., Cho, E. J., Chung, E. S., Shin, W.-H., & Jin, B. K. (2018) · Experimental Neurobiology · doi:10.5607/en.2018.27.4.309 · Cited by 36
Neuroprotective effects of acetyl-l-carnitine (ALC) in a chronic MPTP-induced Parkinson’s disease mouse model: Endothelial and microglial effects
Burks, S. M., Raymick, J. B., Robinson, B. L., Hanig, J. P., & Sarkar, S. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.03.015 · Cited by 38
A Pooling Genome-Wide Association Study Combining a Pathway Analysis for Typical Sporadic Parkinson’s Disease in the Han Population of Chinese Mainland
Hu, Y., Deng, L., Zhang, J., Fang, X., Mei, P., Cao, X., Lin, J., Wei, Y., Zhang, X., & Xu, R. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9331-y · Cited by 38
Photobiomodulation Mitigates Cerebrovascular Leakage Induced by the Parkinsonian Neurotoxin MPTP
Miguel, M. S., Martin, K. L., Stone, J., & Johnstone, D. M. (2019) · Biomolecules · doi:10.3390/biom9100564 · Cited by 37
Caffeine, Through Adenosine A3 Receptor-Mediated Actions, Suppresses Amyloid-β Protein Precursor Internalization and Amyloid-β Generation
Li, S., Geiger, N. H., Soliman, M. L., Hui, L., Geiger, J. D., & Chen, X. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142223 · Cited by 35
Self-citation
Beneficial Role of Coffee and Caffeine in Neurodegenerative Diseases: A Minireview
Yenisetti, S. C., & ., M. (2016) · AIMS Public Health · doi:10.3934/publichealth.2016.2.407 · Cited by 34
Caffeine Protects Against Retinal Inflammation
Conti, F., Lazzara, F., Romano, G. L., Platania, C. B. M., Drago, F., & Bucolo, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.824885 · Cited by 33
Effect of caffeine on the expression of cytochrome P450 1A2, adenosine A2A receptor and dopamine transporter in control and 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine treated mouse striatum
Singh, S., Singh, K., Gupta, S. P., Patel, D. K., Singh, V. K., Singh, R. K., & Singh, M. P. (2009) · Brain Research · doi:10.1016/j.brainres.2009.06.002 · Cited by 34
TRYCAT Pathways Link Peripheral Inflammation, Nicotine, Somatization and Depression in the Etiology and Course of Parkinson’s Disease
Anderson, G., & Maes, M. H. J. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/18715273113129990082 · Cited by 32
Targeting metabolic inflammation in Parkinson’s disease: Implications for prospective therapeutic strategies
Lu, M., & Hu, G. (2011) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2011.05650.x · Cited by 33
Current therapeutic targets and multifaceted physiological impacts of caffeine
Song, X., Kirtipal, N., Lee, S., Malý, P., & Bharadwaj, S. (2023) · Phytotherapy Research · doi:10.1002/ptr.8000 · Cited by 36
Role of dopamine in the recruitment of immune cells to the nigro-striatal dopaminergic structures
Espinosa‐Oliva, A. M., de Pablos, R. M., Soto, M. S., Villarán, R. F., Carrillo-Jiménez, A., Santiago, M., Venero, J. L., Herrera, A. J., Cano, J., & Machado, A. (2014) · NeuroToxicology · doi:10.1016/j.neuro.2014.01.006 · Cited by 29
Potential Role of Caffeine in the Treatment of Parkinson’s Disease
Roshan, M. H. K., Tambo, A., & Pace, N. P. (2016) · The Open Neurology Journal · doi:10.2174/1874205x01610010042 · Cited by 33
Antioxidants and Dementia Risk: Consideration through a Cerebrovascular Perspective
Lam, V., Hackett, M. J., & Takechi, R. (2016) · Nutrients · doi:10.3390/nu8120828 · Cited by 26

Authors: Chen, X., Lan, X., Roche, I., Liu, R., & Geiger, J. D.
Affiliations: University of North Dakota (US)
ORCID: Chen, Xuesong
Geiger, Jonathan D.
Venue: Journal of Neurochemistry
Publisher: Wiley
Published: 2008-10-21
Volume: 107
Issue: 4
Pages: 1147-1157
ISSN: 0022-3042 (ISSN-L)
1471-4159
DOI: 10.1111/j.1471-4159.2008.05697.x
PMC: PMC3692355
OpenAlex: W2006684548
Cited by: 189
References: 71
Citations by year: 2026: 7 · 2025: 9 · 2024: 12 · 2023: 18 · 2022: 11 · 2021: 14 · 2020: 13 · 2019: 11 · 2018: 7 · 2017: 9 · 2016: 13 · 2015: 11 · 2014: 10 · 2013: 10 · 2012: 9
FWCI: 5.47
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Journal of Neurochemistry (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Center for Research Resources (P20RR17699, P20RR017699)
Topics: Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Keywords: caffeine, MPTP, blood-brain barrier dysfunction, Parkinson's disease, striatum, tight junction proteins, occludin, ZO-1, dopaminergic neurons, tyrosine hydroxylase, reactive gliosis, astrocytes, microglia, neuroprotection, neurotoxicity
MeSH terms: Central Nervous System Stimulants, Analysis of Variance, Animals, Blood-Brain Barrier, Caffeine, Corpus Striatum, Disease Models, Animal, Evans Blue, Gene Expression Regulation, Gliosis, Male, Membrane Proteins, Phosphoproteins, RNA, Messenger, Tyrosine 3-Monooxygenase, MPTP Poisoning, Matrix Metalloproteinase 9, Mice, Occludin, Zonula Occludens-1 Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Caffeine protects against MPTP‐induced blood‐brain barrier dysfunction in mouse striatum

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks